company

RETHINK PHARMA AS

4610 KRISTIANSAND S

Return on Equity
88,44 %
Current Ratio
0,78
Debt-to-Equity Ratio
−0
Key figures (NOK)2022
Revenue0
Net Income−130 000
Total Assets518 000
Total Equity−147 000
Income (NOK)2022
Revenue0
Expenditure131 000
Operating Profit−131 000
Financial Income1 000
Financial Costs0
Financial Balance1 000
Earnings Before Tax−130 000
Tax0
Net Income−130 000
Balance (NOK)2022
Total Fixed Assets0
Total Current Assets518 000
Total Assets518 000
Total Retained Equity−177 000
Total Equity−147 000
Total Long-Term Debt0
Total Current Debt665 000
Total Equity and Debt518 000
Cash flow (NOK)2022
Sales Income0
Other Income0
Revenue0
Cost of Goods Sold2 000
Salary Costs0
Depreciation0
Impairment0
Expenditure131 000
Operating Profit−131 000
Financial Income1 000
Financial Costs0
Financial Balance1 000
Dividends0
Net Income−130 000
Balance details (NOK)2022
Goodwill0
Total Intangible Assets0
Real Eastate0
Machinery and Plant Facilities0
Fixtures0
Total Tangible Assets0
Total Fiancial Fixed Assets0
Total Fixed Assets0
Stock421 000
Total Investments0
Cash, Bank1 000
Total Current Assets518 000
Total Assets518 000
Total Equity−147 000
Short-Term Group Debt0
Total Long-Term Debt0
Creditors51 000
Unpaid Taxes0
Dividends0
Other Current Debt613 000
Total Current Debt665 000
Total Equity and Debt518 000
Financial indicators2022
Return on Equity88,44 %
Debt-to-Equity Ratio−0
Operating Profit Margin-
Current Ratio0,78
Quick Ratio2,12
Equity Ratio−0,28
Gross Profit Margin-
RotateRotate your device to see the full table
HomeIndustriesNew CompaniesAbout
🇳🇴Norsk🇬🇧English